Latest News

Regeneron developing antibodies to target omicron as current cocktail loses potency against variant

0

CEO Leonard Schleifer told CNBC Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.

H&R Block sues over Square’s new name ‘Block’

Previous article

How bad is inflation? Even millionaires are worried about it.

Next article

You may also like

Comments

Leave a reply

Your email address will not be published.

More in Latest News